Novo Nordisk ADR (NYSE: NVO) on Monday, plunged -0.49% from the previous trading day, before settling in for the closing price of $124.51. Within the past 52 weeks, NVO’s price has moved between $75.56 and $138.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 14.25% over the last five years. The company achieved an average annual earnings per share of 25.51%. With a float of $3.38 billion, this company’s outstanding shares have now reached $3.38 billion.
The firm has a total of 63370 workers. Let’s measure their productivity.
Novo Nordisk ADR (NVO) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Novo Nordisk ADR is 0.00%, while institutional ownership is 9.15%.
Novo Nordisk ADR (NVO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.80% during the next five years compared to 16.48% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Novo Nordisk ADR (NVO) is currently performing well based on its current performance indicators. A quick ratio of 0.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.44. Likewise, its price to free cash flow for the trailing twelve months is 34.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.70, a number that is poised to hit 0.75 in the next quarter and is forecasted to reach 4.16 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Analysing the last 5-days average volume posted by the [Novo Nordisk ADR, NVO], we can find that recorded value of 2.98 million was lower than the volume posted last year of 4.96 million. As of the previous 9 days, the stock’s Stochastic %D was 25.42%. Additionally, its Average True Range was 2.67.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 66.98%, which indicates a significant increase from 9.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 17.04% in the past 14 days, which was lower than the 27.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $125.64, while its 200-day Moving Average is $102.91. Now, the first resistance to watch is $125.46. This is followed by the second major resistance level at $127.02. The third major resistance level sits at $127.99. If the price goes on to break the first support level at $122.93, it is likely to go to the next support level at $121.96. Now, if the price goes above the second support level, the third support stands at $120.40.
Novo Nordisk ADR (NYSE: NVO) Key Stats
Market capitalization of the company is 419.21 billion based on 4,487,532K outstanding shares. Right now, sales total 33,724 M and income totals 12,151 M. The company made 9,526 M in profit during its latest quarter, and 3,175 M in sales during its previous quarter.
